Pharmaceutical Discount Act

In German pharma jargon, the Pharmaceutical Discount Act (Arzneimittelrabattgesetz) is the umbrella term for the legal framework governing pharmaceutical discount agreements between statutory health insurance funds (GKV) and pharmaceutical manufacturers. There is no single law of that name, the relevant provisions are codified in § 130a of the Social Code Book V (SGB V), supplemented by flanking rules from the GMG, AMNOG, GKV-FinStG and ALBVVG legislative packages.

The core mechanism is simple: a statutory health insurance fund tenders an active substance, for example omeprazole or metoprolol, as a discount agreement. Pharmaceutical manufacturers bid a percentage or absolute discount on their manufacturer ex-factory price. The awarded manufacturer obtains a contractual position under which, pursuant to § 129 SGB V, pharmacies are required to dispense its product exclusively (so-called aut idem substitution). In exchange, the manufacturer secures predictable, near-exclusive supply to millions of insured patients over the contract term.

Economically, § 130a SGB V is the GKV's most powerful cost-control lever in the generics market: roughly 80 % of all generic packages dispensed in Germany today flow through discount agreements. For a manufacturer, the right bidding strategy on a single active-substance tender often determines double-digit million-euro revenues and entire production planning cycles.

Discount agreements above the EU threshold are formally public contracts under procurement law and are tendered via procurement platforms such as DTVP or Subreport ELViS. The health insurer is the contracting authority within the meaning of § 99 GWB, the manufacturers are bidders, and the standard rules apply: publication, right to challenge, review proceedings and the ten-day standstill period under § 134 GWB.

The term should be distinguished from:

• the manufacturer rebate under § 130a (1) SGB V, a statutory mandatory rebate, not contractual,
• the price moratorium under § 130a (3a) SGB V, a statutory price freeze,
• the reimbursement price under § 130b SGB V, the centrally negotiated price for new, patent-protected drugs after AMNOG benefit assessment,
• the reference prices under § 35 SGB V, maximum reimbursement ceilings for entire substance groups.

Only § 130a (8) SGB V governs discount agreements in the narrow sense, the term pharmaceutical companies mean when they talk about a “Rabattvertrag tender".

The legal architecture of the Pharmaceutical Discount Act spans three layers: social law, procurement law and pharmacy law.

Social law basis, § 130a SGB V. Paragraph 8 empowers health insurance funds or their associations to conclude contracts with pharmaceutical companies “on discounts for medicinal products dispensed at their expense". Paragraph 1 regulates the manufacturer rebate (currently 7 % for patent-protected and 10 % for patent-free medicines), paragraph 1a the increased generics rebate, paragraph 2 the price moratorium, paragraph 3a the AMNOG reimbursement price. These statutory rebates apply on top of contractual rebates.

Procurement law classification, GWB and VgV. The German Federal Court of Justice ruled in 2008 (BGH, decision of 2 Dec 2008, X ZB 32/08) that GKV discount agreements are public contracts and subject to procurement law. From the EU threshold of €216,000 (from 1 Jan 2026) onwards, the rules of GWB Part 4 and the VgV apply. Health insurers typically use open procedures, occasionally restricted procedures or competitive procedures with negotiation.

Pharmacy law implementation, § 129 SGB V. This provision obliges pharmacies to substitute: if a discount agreement of the patient's health insurer exists, the discounted product must be dispensed unless pharmaceutical concerns intervene. This substitution duty is the actual economic engine of the system, it gives the awardee a quasi-exclusive market position in the relevant coverage area.

Open-house contracts as a special route. The CJEU clarified in the Falk Pharma decision (C-410/14, 2 Jun 2016) that open-house procedures are not public contracts within the meaning of the procurement directive, because the insurer makes no selection decision. Any qualified manufacturer accepting the published conditions may join. Open-house contracts are therefore possible outside procurement law and not subject to review by the procurement chambers.

Supply security, ALBVVG (2023). The Drug Shortage Combat and Supply Improvement Act flanked § 130a SGB V with a diversification mandate: for antibiotics and critical substances, the insurer must award at least three contracts per lot and reserve one slot for a manufacturer with EU-based production. It also imposes supply and stockpiling duties with contractual penalties for supply failures.

Legal remedies. Pharmaceutical companies may challenge procurement law violations through a timely notice of objection (within 10 days of knowledge) and a subsequent review application before the competent procurement chamber. Immediate complaints to the higher regional court (OLG) procurement senate are admissible against chamber decisions. Federal procurement chambers (Bonn) typically have specialised jurisdiction for discount-agreement disputes.

Techniker Krankenkasse (TK), Germany's largest statutory health insurer, launches its new major generics round effective 1 January 2026: approximately 700 PZN across 70 specialty lots, one of the largest discount-agreement deals of the decade. Take one lot as illustration: pantoprazole 40 mg, gastro-resistant tablets, N1 / N2 / N3, nationwide, 24-month term.

The procedure typically unfolds as follows:

1. Contract notice. TK publishes the contract notice on TED and the DTVP procurement platform. It states the active substance, strength, dosage form, estimated volume over the term, eligibility requirements and award criteria.
2. Eligibility check. Bidders must provide manufacturing authorisation, GMP certification, statutory health-insurance admission and supply-capacity evidence. For antibiotics or supply-critical substances, proof of an EU production site is additionally required.
3. Lot structure. Active substances are split into specialty lots by substance, strength, dosage form and pack size. Bidders may bid on single lots, multiple lots or the full bundle.
4. Bid submission. Each manufacturer calculates its discount on the manufacturer ex-factory price and submits the bid electronically via the procurement platform. The standard binding period is around three months.
5. Evaluation. The main criterion is typically the weighted total discount. For diversified lots, TK awards two or three contracts per lot (multiple award) to safeguard supply.
6. Notification and standstill. After selection, TK informs unsuccessful bidders under § 134 GWB. A 10-day standstill applies, during which unsuccessful manufacturers may still challenge the award before the procurement chamber.
7. Award and contract start. From 1 Jan 2026 pharmacies are obliged to dispense the discounted pantoprazole product to TK-insured patients nationwide.

Manufacturers using Patterno Hit for pharma receive this notice with an active-substance match against their own portfolio on day one of publication, including an automated diff-check against TK's previous 2024 tender, so pricing teams immediately see which strengths, pack sizes or supply duties have changed.

Manufacturers that bid only occasionally on discount agreements often lose at formal hurdles long before pricing:

• Late notice of objection. The 10-day deadline for the notice of objection under § 160 (3) GWB starts when the bidder gains positive knowledge of the alleged violation, not at the end of the bid period. Anyone who only flags a discriminatory requirement after submission is typically time-barred.
• Strength mismatch overlooked. A lot demands pantoprazole 20 mg and 40 mg, but the manufacturer only holds the 40 mg strength in its portfolio. Bidding anyway leads to exclusion, and sometimes loss of bid security. A systematic portfolio check before pricing is mandatory.
• Reimbursement price confused with discount agreement. The reimbursement price under § 130b SGB V is centrally negotiated between the GKV umbrella body and the manufacturer for all insurers. Discount agreements under § 130a (8) SGB V are tendered per insurer. Both regimes coexist and can overlap, overlooking this risks double-discounting.
• Supply duties underestimated. Since the ALBVVG, stockpiling and supply duties have been significantly tightened. Supply failures trigger contractual penalties, and repeat failures lead to termination or, in serious cases, exclusion from future tenders for unreliability under § 124 GWB.
• Open-house ignored as a fallback. Many manufacturers who lose the classic tender overlook the option to join concurrent open-house contracts, often on only slightly worse conditions but without award risk.
• Binding periods miscalculated. A three-month binding period means three months of price commitment without adjustment. Manufacturers exposed to raw-material or FX swings during that window can quickly slip into negative margin.

Successful pharma companies treat discount-agreement tenders as a strategic core process, not as a sales sideline:

• Match the active-substance portfolio digitally and cleanly. Every lot must be checked against the in-house portfolio before bidding: active substance, strength, dosage form, pack sizes, marketing authorisation status. Manual checks regularly produce errors, teams that automate this step (Patterno's pharma BID automatically checks strengths, dosage forms and authorisations against the stored portfolio) typically save one full FTE-day per tender.
• Run a diff-check against the predecessor tender. Health insurers often change only individual clauses in repeat tenders, supply duties, penalties, lot structure. Comparing the new tender word-for-word against its predecessor (which Patterno BID does automatically) quickly reveals where extra cost or new risk is hiding.
• Bottom-up margin model before bid decision. Translate discount offer, supply duty and stockpiling cost into a bottom-up margin model: manufacturer ex-factory price, manufacturer rebate under § 130a (1) SGB V, contractual discount to the insurer, pharmacy rebates, distribution cost. Only then does a valid bid floor emerge.
• Run open-house monitoring in parallel. Alongside large tenders, insurers continuously publish short-term open-house joining offers, often with windows of only a few weeks. A systematic monitoring set-up captures incremental revenue without procurement risk.
• Use diversification rules. If the insurer awards two or three contracts per lot, ranking first is not always the objective. Second or third place means stable revenue share without single-supplier risk. The bidding strategy should plan for this.
• Define the objection strategy early. When the tender documents contain visible problems, disproportionate eligibility criteria, inadmissible lot structure, the notice of objection should be filed within the 10-day deadline, ideally with legal support.
• Cost the bid bond properly. With contractual penalties of up to 30 % of contract value for supply failures, supply risk belongs in the pricing model. A 1–3 % risk premium on the discount rate is market-standard.